322 related articles for article (PubMed ID: 20927731)
1. Interventions for bullous pemphigoid.
Kirtschig G; Middleton P; Bennett C; Murrell DF; Wojnarowska F; Khumalo NP
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD002292. PubMed ID: 20927731
[TBL] [Abstract][Full Text] [Related]
2. Interventions for bullous pemphigoid.
Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD002292. PubMed ID: 37572360
[TBL] [Abstract][Full Text] [Related]
3. Interventions for bullous pemphigoid.
Khumalo N; Kirtschig G; Middleton P; Hollis S; Wojnarowska F; Murrell D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002292. PubMed ID: 16034874
[TBL] [Abstract][Full Text] [Related]
4. Interventions for bullous pemphigoid.
Khumalo N; Kirtschig G; Middleton P; Hollis S; Wojnarowska F; Murrell D
Cochrane Database Syst Rev; 2003; (3):CD002292. PubMed ID: 12917929
[TBL] [Abstract][Full Text] [Related]
5. [Bullous pemphigoid: a review].
Bernard P; Charneux J
Ann Dermatol Venereol; 2011 Mar; 138(3):173-81. PubMed ID: 21397147
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of treatments for bullous pemphigoid.
Khumalo NP; Murrell DF; Wojnarowska F; Kirtschig G
Arch Dermatol; 2002 Mar; 138(3):385-9. PubMed ID: 11902990
[TBL] [Abstract][Full Text] [Related]
7. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
9. Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up.
Kalinska-Bienias A; Kowalczyk E; Jagielski P; Kowalewski C; Wozniak K
Int J Dermatol; 2019 Feb; 58(2):172-177. PubMed ID: 30350359
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Mehndiratta MM; Rajabally YA
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD002062. PubMed ID: 29185258
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
15. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
[TBL] [Abstract][Full Text] [Related]
16. Treatment of bullous pemphigoid.
Fontaine J; Joly P; Roujeau JC
J Dermatol; 2003 Feb; 30(2):83-90. PubMed ID: 12692373
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive agents for myasthenia gravis.
Hart IK; Sathasivam S; Sharshar T
Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
Gagyor I; Madhok VB; Daly F; Somasundara D; Sullivan M; Gammie F; Sullivan F
Cochrane Database Syst Rev; 2015 Nov; (11):CD001869. PubMed ID: 26559436
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Mehndiratta MM
Cochrane Database Syst Rev; 2015 Jan; 1():CD002062. PubMed ID: 25561247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
